ANAB AnaptysBio Inc.: רווח נקי למניה ב-12 החודשים האחרונים

AnaptysBio, Inc. (ANAB) funds the development of immune drugs using royalties from a successful oncology product. The YoY TTM percentage change trend in EPS helps assess profit sustainability over time, while the 250.00 metric indicates the yield status. The model scales through licensing payments, creating growth potential. The development of antibodies to combat asthma and dermatitis is based on unique protein discovery.

This metric measures the growth rate of net earnings per share on a rolling year basis, stripping out accounting adjustments to assess real business efficiency. Given AnaptysBio, Inc. (ANAB) absolute dependence on external contractors (CRO/CMO), this rolling year YoY EPS growth chart helps identify hidden outsourcing costs, determining the company's true margin of safety regardless of GAAP manipulations.